Abstract
The story of cytokines in pregnancy began about 30 years ago, approximately in concomitance with the understanding that cytokines are autocrine-paracrine regulators of physiological processes. Pro-inflammatory cytokines are predominant in the early and late events of gestation, e.g. pregnancy establishment and parturition, both of which have been described as inflammatory-like events. Proinflammatory cytokines are also produced in response to microbes constantly in contact with the female reproductive tract. While a proinflammatory response is beneficial to successful pregnancy, an exaggerated response, as may occur for an unresolved infection, could result in an unfavorable pregnancy outcome in animals and humans. Therapeutic strategies are required to avoid the risks to the health of fetus and mother. In this review, we discuss the involvement of pro-inflammatory cytokines in pregnancy at implantation and parturition, including the pathologies which might be related to an alteration of the cytokine levels. We also deal with the use of anti-cytokines and/or anti-inflammatory mediators to antagonize the action of pro-inflammatory cytokines. Finally we discuss the potential of animal models to evaluate the association of cytokines in the establishment and maintenance of pregnancy.
Keywords: Cytokine, pregnancy, maternal-fetal immunotolerance, implantation, labor, pregnancy disorders, Pro-inflammatory Cytokines, Human Gestation, autocrine-paracrine regulators, paracrine regulators, murine placenta, inflammation, immunosuppression, pre-eclampsia, interferons, interleukins, leukemia inhibitory factor, tumor necrosis factor, transforming growth factors, colony stimulating factors, vascular endothelial growth factors, pleiotropism, redundancy, synergism, mutual antagonism, GM-CSF, Th1/Th2 cytokine dichotomy, myometrium, uterine epithelial cells, estradiol, LPS-activated monocytes, immune response, endocrine disruptors, Macrophage migration inhibitory factor, Interleukin-1, COX-2, intracytoplasmic domain, 11-hydroxysteroid dehydrogenase, post-natal hypertension
Current Pharmaceutical Design
Title: Pro-inflammatory Cytokines in Animal and Human Gestation
Volume: 16 Issue: 32
Author(s): Luana Paulesu, Jayonta Bhattacharjee, Nicoletta Bechi, Roberta Romagnoli, Silke Jantra and Francesca Ietta
Affiliation:
Keywords: Cytokine, pregnancy, maternal-fetal immunotolerance, implantation, labor, pregnancy disorders, Pro-inflammatory Cytokines, Human Gestation, autocrine-paracrine regulators, paracrine regulators, murine placenta, inflammation, immunosuppression, pre-eclampsia, interferons, interleukins, leukemia inhibitory factor, tumor necrosis factor, transforming growth factors, colony stimulating factors, vascular endothelial growth factors, pleiotropism, redundancy, synergism, mutual antagonism, GM-CSF, Th1/Th2 cytokine dichotomy, myometrium, uterine epithelial cells, estradiol, LPS-activated monocytes, immune response, endocrine disruptors, Macrophage migration inhibitory factor, Interleukin-1, COX-2, intracytoplasmic domain, 11-hydroxysteroid dehydrogenase, post-natal hypertension
Abstract: The story of cytokines in pregnancy began about 30 years ago, approximately in concomitance with the understanding that cytokines are autocrine-paracrine regulators of physiological processes. Pro-inflammatory cytokines are predominant in the early and late events of gestation, e.g. pregnancy establishment and parturition, both of which have been described as inflammatory-like events. Proinflammatory cytokines are also produced in response to microbes constantly in contact with the female reproductive tract. While a proinflammatory response is beneficial to successful pregnancy, an exaggerated response, as may occur for an unresolved infection, could result in an unfavorable pregnancy outcome in animals and humans. Therapeutic strategies are required to avoid the risks to the health of fetus and mother. In this review, we discuss the involvement of pro-inflammatory cytokines in pregnancy at implantation and parturition, including the pathologies which might be related to an alteration of the cytokine levels. We also deal with the use of anti-cytokines and/or anti-inflammatory mediators to antagonize the action of pro-inflammatory cytokines. Finally we discuss the potential of animal models to evaluate the association of cytokines in the establishment and maintenance of pregnancy.
Export Options
About this article
Cite this article as:
Paulesu Luana, Bhattacharjee Jayonta, Bechi Nicoletta, Romagnoli Roberta, Jantra Silke and Ietta Francesca, Pro-inflammatory Cytokines in Animal and Human Gestation, Current Pharmaceutical Design 2010; 16 (32) . https://dx.doi.org/10.2174/138161210793797933
DOI https://dx.doi.org/10.2174/138161210793797933 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Development of Anti-Atherosclerosis Therapy Based on the Inflammatory and Proliferative Aspects of the Disease
Current Pharmaceutical Design Targeting the Phosphatidylinositol 3-Kinase/Akt/Mammalian Target of Rapamycin Signaling Network in Cancer Stem Cells
Current Medicinal Chemistry Specific Targeting of HER2-Positive Head and Neck Squamous Cell Carcinoma Line HN5 by Idarubicin-ZHER2 Affibody Conjugate
Current Cancer Drug Targets Can Breast Cancer Stem Cells Evade the Immune System?
Current Medicinal Chemistry Approaches to Optimize Gene Therapy for the Treatment of Hematologic Malignancies: Overcoming the Obstacles
Current Gene Therapy Multifunctional Radiolabeled Nanoparticles for Targeted Therapy
Current Medicinal Chemistry Determination of 7,12-Dimethylbenz[a]Anthracene in Orally Treated Rats by High-Performance Liquid Chromatography and Transfer Stripping Voltammetry
Combinatorial Chemistry & High Throughput Screening miRNA: Small Molecules as Potential Novel Biomarkers in Cancer
Current Medicinal Chemistry B7-H3-targeted Radioimmunotherapy of Human Cancer
Current Medicinal Chemistry A Novel Multiple Tyrosine-kinase Targeted Agent to Explore the Future Perspectives of Anti-Angiogenic Therapy for the Treatment of Multiple Solid Tumors: Cabozantinib
Anti-Cancer Agents in Medicinal Chemistry Monoclonal Antibodies in Cancer Therapy
Current Medicinal Chemistry - Anti-Cancer Agents Breast Cancer: Understanding Sensitivity and Resistance to Chemotherapy and Targeted Therapies to Aid in Personalised Medicine
Current Cancer Drug Targets Aurora B Kinase and Passenger Proteins as Targets for Cancer Therapy
Current Enzyme Inhibition Virus, Oncolytic Virus and Human Prostate Cancer
Current Cancer Drug Targets Novel Approaches for RNA Interference and their Application in Cancer Therapy
Current Pharmacogenomics The Genetic Basis of New Treatment Modalities in Melanoma
Current Drug Targets The Potential of Flavonoids and Tannins from Medicinal Plants as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Anti-Cancer Drug Discovery STAT5 and STAT5 Inhibitors in Hematological Malignancies
Anti-Cancer Agents in Medicinal Chemistry Co-morbidity of Covid-19 and Stenotrophomonas maltophilia in a Patient with Hodgkin's Lymphoma History from North of Iran
Infectious Disorders - Drug Targets